Ontology highlight
ABSTRACT:
SUBMITTER: Peng L
PROVIDER: S-EPMC7413896 | biostudies-literature | 2020 Sep
REPOSITORIES: biostudies-literature
Cancer immunology, immunotherapy : CII 20200429 9
<h4>Background</h4>Selected patients with advanced non-small cell lung cancer (NSCLC) benefit from immunotherapy, especially immune checkpoint inhibitors such as PD-1 (programmed cell death protein 1) inhibitor. Peripheral blood biomarkers would be most convenient to predict treatment outcome and immune-related adverse events (irAEs) in candidate patients. This study explored associations between inflammation-related peripheral blood markers and onset of irAEs and outcome in patients with advanc ...[more]